

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 November 2022 (24.11.2022)



(10) International Publication Number
WO 2022/245675 A1

(51) International Patent Classification:

C12N 15/864 (2006.01) C07K 14/47 (2006.01)
A61K 48/00 (2006.01) A61P 21/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/029328

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

13 May 2022 (13.05.2022)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/189,676 17 May 2021 (17.05.2021) US
63/209,733 11 June 2021 (11.06.2021) US
63/243,944 14 September 2021 (14.09.2021) US
63/253,998 08 October 2021 (08.10.2021) US

(71) Applicant: SAREPTA THERAPEUTICS, INC.
[US/US]; 215 First Street, Cambridge, Massachusetts
02142 (US).

(72) Inventors: ALAM, Maroof; c/o Sarepta Therapeutics,
Inc., 215 First Street, Cambridge, Massachusetts 02142
(US). RODINO-KLAPAC, Louise; c/o Sarepta Therapeu-
tics, Inc., 215 First Street, Cambridge, Massachusetts 02142
(US).

(74) Agent: STEFFE, Eric K. et al.; STERNE, KESSLER,
GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue,
NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PRODUCTION OF RECOMBINANT AAV VECTORS FOR TREATING MUSCULAR DYSTROPHY

(57) Abstract: The present disclosure provides gene therapy vectors, such as recombinant adeno-associated virus (rAAV), produced in mammalian adherent cells cultured in suspension conditions, for expressing a human micro-dystrophin gene. The present disclosure also provides compositions and methods of using these rAAV to treat muscular dystrophy, such as, e.g., Duchenne Muscular Dystrophy.

WO 2022/245675 A1